✦ LIBER ✦

[649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA

✍ Scribed by M.L. Shiftman; R. Ghalib; E. Lawitz; B. Freilich; S.C. Gordon; P.Y. Kwo; T.R. Riley; E. Schiff; S. Flamm; I.M. Jacobson; N.N. Zein; A. Reuben; M. Swaim; D. Bright; M. Al-Adhami; J. Lekstrom-Himes; F.E. Massari; J.G. McHutchison

Book ID: 118567120
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 252 KB
Volume: 46
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(07)62247-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

730 Early viral response to CPG 10101, i

730 Early viral response to CPG 10101, in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response

✍ J.G. McHutchison; R. Chalib; E. Tawitz; P. Kwo; B. Freilich; A. Muir; E. Masciar 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Emergence of occult minority genotype 2b

Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-α 2b and ribavirin

✍ A.J. Buckton; R. Kulasegaram; S.L. Ngui; M. Fisher; R. James; S. Rangarajan; C.G 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 362 KB

A matched case-controlled study of 48 an

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response

✍ Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract Substitution of amino acid (aa) 70 and 91 in the core region of HCV genotype 1b is a useful pretreatment predictor of efficacy of 48‐week peginterferon (PEG‐IFN) plus ribavirin (RBV) therapy. Here, we determined the efficacy of 72‐week PEG‐IFN/RBV and the predictive factors to such ther